Bicycle Therapeutics (BCYC) Net Income towards Common Stockholders (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$50.3 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 36.25% year-over-year to -$50.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$190.4 million (up 21.43% YoY) and the FY2025 annual result came in at -$219.0 million, down 29.54% from the prior year.
• Net Income towards Common Stockholders improved to -$50.3 million in Q2 2026, from -$60.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$20.2 million in Q4 2025 to a low of -$79.0 million in Q2 2025.
• A 5-year average of -$44.0 million and a median of -$45.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 61.13% in 2025, down 128.72% in 2025.
• Tracing BCYC's Net Income towards Common Stockholders over 5 years: stood at -$30.0 million in 2022, then slumped by 63.78% to -$49.1 million in 2023, then slipped by 5.61% to -$51.9 million in 2024, then soared by 61.13% to -$20.2 million in 2025, then plunged by 149.74% to -$50.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$50.3 million (Q2 2026), -$60.8 million (Q1 2026), and -$20.2 million (Q4 2025), per Business Quant data.